Joint analysis from the European Medicines Agency and the US Food and Drug Administration (FDA) has shown that the regulatory bodies are highly aligned in the majority of marketing authorization decisions.
In an Aug. 16, 2019 press release, EMA highlighted the alignment finding from the joOriginal Article